Everything below concerns peptide fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-03. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
=== Support groups === The Juvenile Scleroderma Network is an organization dedicated to providing emotional support and educational information to parents and their children living with juvenile scleroderma, supporting pediatric research to identify the cause of and the cure for juvenile scleroderma, and enhancing public awareness. In the US, the Scleroderma Foundation is dedicated to raise awareness of the disease and assist those who are affected. The Scleroderma Research Foundation sponsors research into the condition. Comedian and television presenter Bob Saget, a board member of the SRF, directed the 1996 ABC TV movie For Hope, starring Dana Delany, which depicts a young woman fatally affected by scleroderma; the film was based on the experiences of Saget's sister Gay. Scleroderma and Raynaud's UK is a British charity formed by the merger of two smaller organisations in 2016 to provide support for people with scleroderma and fund research into the condition.
=== Graves' disease === Graves' disease is a condition characterized by development of autoantibodies to thyroid-stimulating hormone receptors. The binding of the autoantibodies to the receptors results in unregulated production and release of thyroid hormone, which can lead to stimulatory effects such as rapid heart rate, weight loss, nervousness, and irritability. Other symptoms more specific to Graves' disease include bulging eyes and swelling of the lower legs.
A specific binding site in collagen II has been identified. It is specific for mesenchymal cells. Functions include: Chondrocyte proliferation and bone growth; regulation of cell proliferation, cell adhesion and induction of MMP expression.
== Modern applications == Non-radioactivity-related uses of thorium have been in decline since the 1950s due to environmental concerns largely stemming from the radioactivity of thorium and its decay products. Most thorium applications use its dioxide (sometimes called "thoria" in the industry), rather than the metal. This compound has a melting point of 3300 °C (6000 °F), the highest of all known oxides; only a few substances have higher melting points. This helps the compound remain solid in a flame, and it considerably increases the brightness of the flame; this is the main reason thorium is used in gas lamp mantles. All substances emit energy (glow) at high temperatures, but the light emitted by thorium is nearly all in the visible spectrum, hence the brightness of thorium mantles. Energy, some of it in the form of visible light, is emitted when thorium is exposed to a source of energy itself, such as a cathode ray, heat, or ultraviolet light. This effect is shared by cerium dioxide, which converts ultraviolet light into visible light more efficiently, but thorium dioxide gives a higher flame temperature, emitting less infrared light. Thorium in mantles, though still common, has been progressively replaced with yttrium since the late 1990s. According to the 2005 review by the United Kingdom's National Radiological Protection Board, "although [thoriated gas mantles] were widely available a few years ago, they are not any more." Thorium is also used to make cheap permanent negative ion generators, such as in pseudoscientific health bracelets.
Initial strikes killed Iran's supreme leader Ali Khamenei and other top Iranian officials, and hundreds of Iranians were killed or injured. The Iranian Red Crescent said 24 provinces were affected. The strikes were coupled with cyberattacks on Iranian infrastructure, media, and phone apps, with messages calling on Iranians to rise up against their government. The cyberattacks resulted in a near-total internet blackout in Iran, lasting over 60 hours with connectivity dropping to as low as 1% of normal levels, disrupting government communications, state media, and public services. Iran restricted internet access, allowing access only to government-approved users until 26 May. On 28 February, Trump released a statement saying the purpose of the strikes was regime change, citing Iran's support for non-state actors such as Hamas and Hezbollah, killings of protesters, chants of "Death to America", and alleged history of attacking US civilians and soldiers, as well as the Iran hostage crisis. Trump and Benjamin Netanyahu warned of the potential threat of nuclear weapons in Iran and called on Iranians to overthrow their government. Israeli defense minister Israel Katz labeled the strikes a "pre-emptive attack" intended to "remove threats to...Israel". Iran denied that it intended to attack the US.
Sources: en.wikipedia.org
Agnolín, Bogan & Lucero (2026) consider Balaena pampaea, Notiocetus romerianus and N. platensis to be nomina dubia, interpreting the fossil material of N. platensis as remains of an indeterminate baleen whale, and interpreting fossils of B. pampaea and N. romerianus as remains of an indeterminate balaenid. Lambert et al. (2026) report shark feeding traces on bones of cetacean specimens from the Pliocene Kattendijk Formation (Belgium), including evidence of a bluntnose sixgill shark feeding on a right whale Balaenella brachyrhynus and evidence of Carcharodon plicatilis feeding on a member of the genus Casatia. López-Galán, Ferrón & Botella (2026) study ecomorphological variation of extant and extinct filter-feeding cetaceans, pachycormiform fishes and selachians, interpreting members of the three groups as repeatedly converging toward analogous functional designs, but also interpreting their convergent evolution as influenced by lineage-specific constraints.
To assist with settling on the best form of treatment for cauliflower ear, Yotsuyanagi et al. created a classification system for deciding when surgery is needed and as a guide to what the best approach would be.
=== Engine coolant standards === The Volkswagen Group has been particularly committed to the development of coolants and their standards (VW TL 774) in collaboration with Haertol Chemie from Magdeburg. VW standards include: G11, G12, G12+, G12++, G13 and G12evo. Another company involved in the development is BASF (Glysantin), whose standards are: G30, G40, G48, G05, G33, and G34. Volkswagen Group:
Westbrook* (1968), writer, son of syndicated columnist Sheilah Graham Westbrook Phillip Lopate (1964), essayist and fiction writer Ron Padgett (1964), poet and translator, winner of the Shelley Memorial Award in 2009 and Robert Frost Medal in 2018 Steven Millhauser (1965), novelist and winner of the Pulitzer Prize for Fiction for Martin Dressler: The Tale of an American Dreamer Aaron Fogel (1967), poet Eric Van Lustbader (1967), espionage and thriller novelist, writer of Jason Bourne novels Thomas Hauser (1968), author of nonfiction and biographer David Shapiro (1968), poet, literary critic, professor at William Paterson University Hilton Obenzinger (1969), novelist, poet, history and criticism writer Paul Auster (1970), postmodern writer; author of The New York Trilogy, Moon Palace, and the Brooklyn Follies Bob Holman (1970), poet and activist identified with the oral tradition David Lehman (1970), poet, editor of The Best American Poetry series Joshua Rubenstein (1971), writer, winner of a National Jewish Book Award in 2002 Alex Abella (1972), Cuban-American writer Brad Gooch (1973), writer, professor of English at William Paterson University John Prados (1973), author and historian on World War II and the Cold War Todd McEwen (1975), writer, professor at the University of Kent Stephen O'Connor (1975), writer and professor at Sarah Lawrence College Damien Bona (1977), chronicler of the Academy Awards Mason Wiley (1977), co-author of The Official Preppy Handbook Kevin Baker (1980), novelist and freelance journalist Jeffrey Harrison (1980), poet who won the 1988 Amy Lowell Poetry Travelling Scholarship Lou Antonelli (1981), science fiction writer Douglas Sadownick (1981), writer and psychologist Michael Friedman (1982), novelist and author Michael Azerrad (1983), author, journalist, musician Thomas Dyja (1984), writer, historian, winner of the 1997 Casey Award David Rakoff (1986), comedic essayist Louise Wareham Leonard (1987), writer Al Weisel (1987), freelance writer Adrienne Brodeur (1988), author, program director at Aspen Institute Glen Hirshberg (1988), author, recipient of the 2007 Shirley Jackson Award Adam Mansbach (1988), author and former professor of literature at Rutgers University–Camden Darryl Pinckney (1988), novelist, playwright, and essayist Mako Yoshikawa (1988), novelist, professor at Emerson College Ben Coes (1989), author of political thriller and espionage novels Wade Graham (1989), author, historian, environmentalist G. Winston James (1989), poet, author, activist Robert Salkowitz (1989), author on technology innovation Carol Guess (1990), novelist and poet; professor at Western Washington University John Reed (1990), novelist; author of Snowball's Chance David S. Levinson (1991), short-story writer and novelist Robert Kolker (1991), writer, author of Hidden Valley Road Kelly Link (1991), Hugo Award-winning author; founder of Small Beer Press; editor of St. Martin's Press's Year's Best Fantasy and Horror Loren Goodman (1991), postmodern poet, professor at Underwood International College Andrew Carroll (1992), author, editor, activist, and historian Jordan Davis (1992), poet John Bemelmans Marciano (1992), children's book author and illustrator, grandson of Ludwig Bemelmans, author of Madeline Marie Mutsuki Mockett (1992), writer Melissa de la Cruz (1993), writer known for work in young adult fiction Jay Michaelson (1993), writer and LGBTQ activist Maxine Swann (1994), fiction writer Robert Westfield (1994), writer who won two Lambda Literary Awards Megan McCafferty (1995), chick lit writer, Jessica Darling series, which were plagiarized by Kaavya Viswanathan Tova Mirvis (1995), author Saleemah Abdul-Ghafur (1996), author and Islamic activist Fredrik Stanton (1996), author of Great Negotiations and former publisher for the Columbia Daily Spectator Aravind Adiga (1997), Man Booker Prize-winning novelist Jamel Brinkley (1997), author, winner of the 2018 Ernest J. Gaines Award for Literary Excellence John Coletti (1997), author Gotham Chopra (1997), author, son of health advocate Deepak Chopra Lauren Grodstein (1997), author, professor of Rutgers University–Camden Abdi Nazemian (1998), Iranian-American author, winner of the 2017 Lambda Literary Award for Debut Fiction Trevor Shane (1998), writer Daniel Alarcón (1999), novelist Katherine Howe (1999), novelist, author of The Physick Book of Deliverance Dane Rebecca Pawel (1999), author of mystery novels; winner of the 2004 Edgar Allan Poe Award for Best First Novel Alex Marzano-Lesnevich (2001), author, winner of a 2018 Lambda Literary Award and Chautauqua Prize Fiona Sze-Lorrain (2003), French writer, poet, translator, musician Ben Dolnick (2004), writer, son of biographer Edward Dolnick, member of the Ochs-Sulzberger family that owns The New York Times Danielle Valore Evans (2004), fiction writer Adam Gidwitz (2004), author of best selling children's books Alaya Dawn Johnson (2004), author and winner of the 2015 Andre Norton Award Tongo Eisen-Martin (2004), poet laureate of San Francisco Sidik Fofana (2005), public school teacher and writer, winner of a 2023 Whiting Award Victoria Loustalot (2006), writer of memoir and essays Crystal Hana Kim (2009), writer, If You Leave Me Morgan Parker (2010), poet and Cave Canem Fellow Rachel Heng (2011), Singaporean writer Ben Philippe (2011), author, screenwriter, recipient of the 2020 William C. Morris Award Rowan Hisayo Buchanan (2012), British-American writer, recipient of the Betty Trask Award and the Authors' Club Best First Novel Award Sylvia Khoury (2012), writer and playwright, recipient of a 2021 Whiting Award Yanyi (2013), poet
=== Clinical laboratory === On 3 October 2013, a special ceremony was held at the Sindh Institute of Urology and Transplantation (SIUT) Chablani Medical Center to dedicate its clinical laboratory in memory of Tanveer Abbasi a renowned writer, poet and intellectual of Sindh.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.